It’s Not Over Yet For GlycoMimetics Inc (NASDAQ: GLYC)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

GlycoMimetics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of GlycoMimetics Inc is $195.93M. A total of 0.72 million shares were traded on the day, compared to an average of 351.30K shares.

In the most recent transaction, Rock Edwin bought 30,403 shares of GLYC for 1.38 per share on Sep 22 ’23. After the transaction, the Chief Medical Officer now owns 375,403 company shares. In a previous transaction on Sep 21 ’23, Rock Edwin bought 35,000 shares at 1.38 per share. GLYC shares that Chief Medical Officer owns now total 345,000.

Among the insiders who sold shares, Hahn Brian M. disposed of 3,700 shares on May 17 ’23 at a per-share price of $1.95. This resulted in the SVP Finance, CFO holding 53,143 shares of GLYC after the transaction. In another insider transaction, JUNIUS DANIEL M bought 30,000 shares at $1.56 per share on May 10 ’23. Company shares held by the Director now total 93,250.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, GLYC has a high of $3.53 and a low of $1.11.

As of this writing, GLYC has an earnings estimate of -$0.15 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.15.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. GLYC’s latest balance sheet shows that the firm has $90.25M in Cash & Short Term Investments as of fiscal 2021. There were $1.92M in debt and $11.82M in liabilities at the time. Its Book Value Per Share was $0.60, while its Total Shareholder’s Equity was $81.60M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GLYC is Buy with a score of 5.00.

Most Popular

Related Posts